secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-08-21T11:53:12+00:00
Accession:  0001104659-26-099390
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus plans $230M Dutch auction tender offer at $5.00-$5.75/share
-------------------------------------------------------------------

- Tender offer to repurchase up to $230M of common shares at $5.00-$5.75/share, funded from cash on hand.
- Offer expected to commence ~Aug 24, 2026 and expire ~Sep 29, 2026; subject to Canadian/US exemptive relief.
- CEO cites March 2026 Moderna settlement and July 2026 initial payment as funding source for the buyback.
- J.P. Morgan Securities LLC is dealer-manager; Georgeson LLC and TSX Trust are info agent and depositary.
- Company will continue to enforce LNP patent rights against Pfizer and BioNTech alongside licensee Genevant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000110465926099390/0001104659-26-099390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000110465926099390/tm2623751d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-099390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer